Genzyme Next-Generation Osteoarthritis Candidate Hylastan Found Not Superior To Steroids
This article was originally published in The Pink Sheet Daily
Executive Summary
Failed therapy is now on the back burner, as focus turns to approval and introduction of single-treatment viscosupplementation product Synvisc-One, company tells “The Pink Sheet” DAILY.